Provided by Tiger Trade Technology Pte. Ltd.

Tenaya Therapeutics Inc

0.6671
+0.085714.74%
Volume:3.89M
Turnover:2.48M
Market Cap:144.43M
PE:-0.89
High:0.6748
Open:0.6307
Low:0.6008
Close:0.5814
52wk High:2.35
52wk Low:0.3600
Shares:216.51M
Float Shares:205.84M
Volume Ratio:21.27
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7500
EPS(LYR):-1.3101
ROE:-96.44%
ROA:-49.48%
PB:1.74
PE(LYR):-0.51

Loading ...

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

Reuters
·
43 mins ago

Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration

TIPRANKS
·
51 mins ago

BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics

Reuters
·
1 hour ago

Tenaya Therapeutics Inc - Co to Validate up to 15 Gene Targets Under Agreement

THOMSON REUTERS
·
1 hour ago

Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

THOMSON REUTERS
·
1 hour ago

Tenaya Therapeutics Inc - to Receive up to $10 Mln Upfront and up to $1.13 Bln in Milestone Payments

THOMSON REUTERS
·
1 hour ago

Tenaya Therapeutics to Join Leerink Partners Global Healthcare Conference in Miami

Reuters
·
Mar 03

e.l.f., Crown Castle, DoorDash, Stag, Tenaya Shake-Up

TIPRANKS
·
Feb 28

Tenaya Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
Feb 28

Column Group III GP, LP Disposes of Tenaya Therapeutics Common Shares

Reuters
·
Feb 27

Column Group III GP, LP reports disposal of Tenaya Therapeutics common shares

Reuters
·
Feb 25

Major Tenaya Therapeutics Stake Dumped by Key Shareholder in Eye‑Catching Move

TIPRANKS
·
Feb 13

Column Group III GP, LP Reports Disposal of Tenaya Therapeutics Inc. Common Shares

Reuters
·
Feb 13

Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan

TIPRANKS
·
Jan 31

Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise

Simply Wall St.
·
Jan 23

Tenaya Therapeutics: 2026 Clinical Milestones, FDA Pivotal Pathway, and Strengthened Balance Sheet Support Buy Rating

TIPRANKS
·
Jan 10

Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating

TIPRANKS
·
Jan 10

BRIEF-Tenaya Therapeutics Announces 2026 Strategic Priorities

Reuters
·
Jan 09

Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027

Reuters
·
Jan 09

Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-201 in 2026

THOMSON REUTERS
·
Jan 09